Zylet (loteprednol etabonate/tobramycin ophthalmic suspension) / Bausch Health - LARVOL DELTA

Alembic Pharmaceuticals Ltd on Thursday said it has received final approval from the US health regulator for its generic version of Loteprednol Etabonate and Tobramycin ophthalmic suspension used for treatment of eye infection. (Business Standard) - "The approval granted by the US Food & Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) Loteprednol Etabonate and Tobramycin Ophthalmic Suspension of strength 0.5 per cent/0.3 per cent (5 mL and 10 mL), Alembic Pharmaceuticals Ltd said in a regulatory filing."

ANDA • Ophthalmology

Real-World Use of Loteprednol Etabonate 0.5%/Tobramycin 0.3% Ophthalmic Suspension for the Treatment of Ocular Surface Inflammatory Conditions. (PubMed, Clin Ophthalmol) - "Where recorded, most patients (83%) were noted as having their condition resolved/resolving at the first or second follow-up visit. LE/T appears to have a high level of safety when used for the management of various ocular surface inflammatory conditions encountered in optometric practice."

Journal • Real-world evidence • Conjunctivitis • Corneal Abrasion • Dry Eye Disease • Immunology • Infectious Disease • Inflammation • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology

Retrospective analysis of the common uses of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in clinical practice (ARVO 2022) - "LE/T appears to have been well-tolerated when used for the management of various ocular inflammatory conditions encountered in optometric practice. Most patient charts reflected the resolution of the baseline condition with the use of LE/T."

Retrospective data • Conjunctivitis • Corneal Abrasion • Dry Eye Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology

Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial (clinicaltrials.gov) - P1 | N=48 | Completed | Sponsor: Second Affiliated Hospital of Nanchang University

New P1 trial • Conjunctivitis • Dry Eye Disease • Ocular Infections • Ocular Inflammation • Ophthalmology

CORNEAL MELT FOLLOWING EPITHELIUM-OFF CROSSLINKING: ABOUT A NOVEL CASE. (ESCRS-WM 2022) - "He was also prescribed Loteprednol Etabonate 0.5% and Tobramycin 0.3% , but did not use it... Management of thin corneas is a challenge for the ophthalmologist due to the potential sight-threatening complications. Crosslinking is currently evolving towards a patient-tailored treatment strategy. To this aim, the elaboration of clinical and technical check-lists for thin corneas would be helpful to prevent the onset of such complications."

Clinical • Ophthalmology

Review of Loteprednol Etabonate 0.5%/Tobramycin 0.3% in the Treatment of Blepharokeratoconjunctivitis. (PubMed, Ophthalmol Ther) - "Results of published studies indicate that LE/T is effective in the treatment of blepharokeratoconjunctivitis in adults, with similar efficacy as dexamethasone 0.1%/tobramycin 0.3%, but is associated with a lower risk of clinically significant increases in intraocular pressure as demonstrated in both efficacy and safety studies and studies with healthy volunteers...Separately, tobramycin demonstrated potent in vitro activity against most bacterial species associated with blepharitis. In conclusion, published data demonstrate the utility of LE/T for the treatment of the various clinical manifestations of blepharokeratoconjunctivitis in adults."

Journal • Review • Cataract • Conjunctivitis • Dry Eye Disease • Immunology • Infectious Disease • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Loteprednol 0.25% (Eysuvis) for dry eye disease. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Dry Eye Disease • Ophthalmology

[VIRTUAL] In Vitro Potency of Tobramycin Against Common Bacterial Pathogens Implicated in Blepharitis (ARVO 2021) - "Tobramycin demonstrated low MICs against most bacterial species associated with blepharitis, including staphylococci and most methicillin-resistant strains thereof. Together with previous published clinical studies, these data support the use of combination loteprednol etabonate 0.5%/tobramycin 0.3% in the treatment of blepharitis, including in staphylococcal blepharitis."

Preclinical • Dry Eye Disease • Ocular Inflammation • Ophthalmology

Novel Acetylcholinesterase Inhibitors Based on Uracil Moiety for Possible Treatment of Alzheimer Disease. (PubMed, Molecules) - "In this study, novel derivatives based on 6-methyluracil and condensed uracil were synthesized, namely, 2,4-quinazoline-2,4-dione with ω-(ortho-nitrilebenzylethylamino) alkyl chains at the N atoms of the pyrimidine ring...The data from in vitro experiments show that the most active compounds exhibit affinity toward acetylcholinesterase within a nanomolar range, with selectivity for acetylcholinesterase over butyrylcholinesterase reaching four orders of magnitude. In vivo biological assays demonstrated the potency of these compounds in the treatment of memory impairment using an animal model of Alzheimer disease."

Journal • Alzheimer's Disease • CNS Disorders

Punctal Congestion Syndrome: A Reversible, Functional Punctal Stenosis Causing Epiphora in the Setting of Chronic Pretarsal Conjunctivitis. (PubMed, Ophthalmic Plast Reconstr Surg) - "Functional punctal stenosis is associated with topical ophthalmic preparations, especially preserved corticosteroids and antibiotic-corticosteroid combinations. Treatment consists of removal of all preserved eyedrops. Symptoms often improve over several months."

Journal • Allergy • Conjunctivitis • Immunology • Ocular Inflammation • Ophthalmology

Use of cognitive enhancers: methylphenidate and analogs. (PubMed, Eur Rev Med Pharmacol Sci) - "The rapid expansion of methylphenidate analogs onto the drug market in the past few years makes likely the occurrence of intoxications and fatalities in the next years. Careful monitoring and systematic control of methylphenidate analogs should be undertaken to reduce the uprising threat, and education efforts should be made among high-risk populations."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders

Influence of Tethered Ions on Electric Polarization and Electrorheological Property of Polymerized Ionic Liquids. (PubMed, Molecules) - "In this study, three PILs with same mobile anions but different tethered countercations (e.g., poly(dimethyldiallylammonium) P[DADMA], poly(benzylethyl) trimethylammonium P[VBTMA], and poly(1-ethyl-4-vinylimidazolium hexafluorophosphate) P[CVIm]) are prepared and the influence of tethered countercations on the ER property of PILs is investigated...By combining dielectric spectra analysis with DFT calculation and activation energy measurement, it can clarify that the influence of tethered counterions on ER property is mainly associated with ion-pair interaction energy that is affecting ionic conductivity and interfacial polarization induced by ion motion. P[DADMA] has the smallest ion-pair interaction energy with mobile ions, which can result in the highest ionic conductivity and the fastest interfacial polarization rate for its strongest ER property."

Journal

A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis (clinicaltrials.gov) - P4; N=20; Completed; Sponsor: Zhongshan Ophthalmic Center, Sun Yet-sen University

New P4 trial • Biosimilar • Conjunctivitis • Dry Eye Disease • Ocular Infections • Ocular Inflammation • Ophthalmology

Effect of Topical Periocular Steroid Use on Intraocular Pressure: A Retrospective Analysis. (PubMed, Ophthalmic Plast Reconstr Surg) - "Periocular steroid treatment causes a statistically significant rise in IOP in eyes with higher baseline IOP measurements, the risk of which increases with follow up. While this change is not always correlated with a clinically significant rise in IOP, clinicians should monitor more closely patients at greatest risk of steroid response."

Journal • Retrospective data

Don’t shy away from steroid use for surgery patients (Optometry Times) - "Lotemax SM was also designed to be patient-friendly with the moisturizing ingredients glycerin and propylene glycol, a pH close to that of human tears and the lowest preservative percentage (0.003% benzalkonium chloride), in a loteprednol etabonate formulation. The same was done by Kala Pharmaceuticals with the introduction of its steroid Inveltys (loteprednol etabonate ophthalmic suspension 1%), which utilized Kala’s proprietary AMPPLIFY Drug Delivery Technology to enhance penetration into target tissues of the eye."

Online posting